Real Endpoints to host Reimbursement Symposium this November

DISRUPTORS: Revolutionizing Drug/Dx Reimbursement, Nov 1-2, 2012, Philadelphia, PA
Designed to bring together payers, providers, pharma to discuss both the promise and challenges of recent attempts to improve care and cost efficiency. Read on

Online PR News – 09-August-2012 – Westport, CT – Adherence. Diagnostics. Palliative Care. What to prioritize?

At the Real Endpoints Symposium you will learn from these disruptors whose innovations in product reimbursement strategy are creating a new landscape for how healthcare products are valued, bought and used:

Rob Epstein, MD, former CMO, Medco and President, Medco Research; Ezekiel Emanuel, MD, Chair, Department of Medical Ethics and Health Policy, Perelman School of Medicine and The Wharton School, Univ. of Pennsylvania; Carolyn Clancy, MD, Director, AHRQ
Robert Galvin, MD, CEO, Equity Healthcare; Michael Sherman, MD, CMO, Harvard Pilgrim
Ira Klein, MD, Chief of Staff to CMO, Aetna; Kim Caldwell, Director, Pharmacy, Professional Affairs (previously Director, Competitive Health Analytics) Humana;Martin Mackay, PhD, President, R&D, AstraZeneca; Jack Bailey, SVP, Policy, Payers & Vaccines, GlaxoSmithKline; Winston Wong, PharmD, AVP, Pharmacy Management, CareFirst BlueCross BlueShield; Ted Snelgrove, Chief Commercial Officer, Crescendo Bioscience; Jon Resnick, VP RWE Solutions, IMS Health; Marcus Wilson, President, Healthcore (Wellpoint Inc.); Josh Benner, MD, CEO, RxAnte; Annalisa Jenkins, EVP Head of Global Development and Medical, Merck Serono; William Shrank, MD, Director, Rapid Cycle Innovation, CMS
Brian Sweet, Executive Director, Healthcare Alliances, AstraZeneca; Kristin Pothier, Partner, Health Advances; Roger Longman, CEO, Real Endpoints, LLC; Ellen Licking, Senior Analyst, Real Endpoints; Melanie Senior, Senior Analyst, Real Endpoints

The Future of Healthcare is About Measuring – and Proving — Value. Find out how best to do that at the Real Endpoints Symposium.